When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The head of Ozempic maker Novo Nordisk A/S is among business executives who are meeting the Danish prime minister to discuss ...

Capital Investment Advisors LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 12.1% during ...

Brookstone Capital Management cut its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 9.9% in the fourth quarter, ...

On Monday, Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.62 which represents a decrease of $-1.64 or -1.90% from the prior close of $86.26. The stock opened at $84.42 and touched a ...

We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...

In the company's third-quarter report in October, Lilly reported sales of both Mounjaro and Zepbound that missed expectations, as wholesalers cut inventory after bulking up on supply in the previous ...

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

A list of pharmaceutical representatives at the table when the Biden administration negotiated Medicare drug prices reveals ...

There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...

Novo Nordisk A/S (NVO) stock saw a modest uptick, ending the day at $86.26 which represents a slight increase of $0.62 or 0.72% from the prior close of $85.64. The stock opened at $87.22 and touched a ...